Peach & Lily Copper Peptide review: what the advertised 0.2% leaves open

Keep 0.2% attached to its actual wording

The introductory product paragraph advertises “0.2% copper peptide” within a serum also described with hyaluronic acid, amino acids and squalane. The official record supports reporting that exact manufacturer claim. It does not support calling the figure this publication’s independently measured concentration.

The examined text does not identify an assay, certificate, purity specification or mass basis that resolves whether the percentage refers to pure active material, a supplied solution or another formulation definition. Preserving that gap is different from declaring the number false. The grade-and-purity guide explains why a numerical declaration still needs its own analytical definition.

The declaration gives the headline a wider setting

Copper Tripeptide-1 appears in the complete captured ingredient list. The declaration also includes a range of other peptides, humectants and formulation ingredients. This makes the serum’s identity broader than the copper headline alone. The manufacturer list supplies names; it does not disclose the individual amounts of every constituent.

The list and advertised percentage are therefore complementary records, rather than interchangeable proof. One establishes what names the company declares, while the other records a specific quantitative claim. Neither permits the inference that a favorable finished-serum result came entirely from the copper-named ingredient.

Twelve additional peptides is a count

The product explanation separately refers to copper peptides plus twelve additional peptides. That count describes the breadth of the manufacturer’s peptide story. It does not mean twelve additional percentage points, equal amounts of each peptide or a sum that can be added to 0.2%. Peptide-count wording.

A multi-ingredient mixture also makes causal attribution a different question from whether several ingredients are present. This review did not find a copper-isolated comparison in the examined product passages. The COSRX review provides a separate route into reading a peptide count without translating it into a common strength unit.

The result percentages describe reported responses

The “Real Results” panel reports that 96% noticed a visible improvement in firmness and that 91% saw fine lines visibly smoothed. Other entries concern bounce, forehead lines, smoothness and a more youthful appearance. These are attributed brand result statements, not ingredient percentages or the magnitude of an improvement in every participant.

The distinction matters: a fraction of people reporting an improvement is different from an average percentage change in an assessed feature. FDA’s outcome-assessment vocabulary distinguishes different sources of assessment. That framework does not classify or qualify this brand study, whose full methods are not present in the selected record.

Footnotes do not all refer to the same evidence

The starred result panel is labeled “Brand study results.” A separate double-star note identifies before-and-after images as third-party consumer-study results. The saved source therefore does not justify describing every numerical result as independently reproduced third-party evidence. The different qualifications should remain attached to their respective material.

The examined panel does not identify the result study’s participant count, full protocol, control conditions or complete report. This prevents assessment of those details here without proving they do not exist elsewhere. The study-endpoint guide explains why the assessment and denominator are part of a result, rather than optional decoration.

The distinction is substantive even before any comparison with another brand. A photograph, a participant’s impression and a scored appearance finding would require their own descriptions. The brief panel does not disclose enough to reconstruct those relationships. This review consequently retains the source’s “noticed,” “saw” and “felt” wording instead of assigning every entry to one unstated measuring procedure. The missing denominator also prevents converting these percentages into a number of responding participants.

A scientific citation is a separate document

The page’s matrix discussion names scientific references, including Shin 2019 and Fisher 2008. Those references occur within a broader rationale for the product’s ingredients. Their presence in the manufacturer text is not evidence that this review obtained either complete paper or verified a study of the current finished serum.

The cited titles cannot close the missing percentage specification or supply the omitted brand-study methods. A rationale about an ingredient, a product composition claim and a finished-product result can each be useful while supporting different propositions. This analysis leaves those propositions separate instead of treating the bibliography as a certificate for the 0.2% claim.

The record is informative without becoming a ranking

Peach & Lily provides a named serum, a complete captured declaration, an explicit copper-peptide percentage and several appearance statements with distinct source notes. The unresolved analytical basis and study details remain material limits. The official page does not establish how this product compares clinically with a differently described blend.

The Biossance review follows a separate whole-serum claim question, while the original comparison keeps unlike records visible together. Those reading options do not imply a numerical winner. The defensible assessment is of the disclosed evidence, rather than a predicted result for a reader.